In a decision with broad implications for the pharmaceutical industry, a U.S. appeals court recently restricted wide-ranging patent claims for antibody treatments, a ruling legal experts say may force biologics makers to re-examine patent protections for their products.
In this instance, Amgen (AMGN) and Sanofi (SNY) were battling over the market for injectable cholesterol-lowering medicines called PCSK9 inhibitors. For the past several years, the companies have been locked in patent disputes, but earlier this month the appeals court decided that two Amgen patents for its Repatha cholesterol medication were invalid.
I am confused about my membership. I want to pay ontime. please advise.
Comments are closed.